Theravance Biopharma’s (TBPH) Hold Rating Reaffirmed at JonesTrading

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “hold” rating reissued by investment analysts at JonesTrading in a research report issued on Monday,Benzinga reports.

Other equities research analysts have also issued research reports about the company. HC Wainwright boosted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. TD Cowen lifted their price target on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Weiss Ratings downgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. Finally, Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Theravance Biopharma presently has an average rating of “Hold” and an average target price of $21.40.

Theravance Biopharma Stock Performance

NASDAQ:TBPH traded down $0.43 during trading hours on Monday, reaching $17.20. The company’s stock had a trading volume of 1,623,650 shares, compared to its average volume of 530,941. The firm has a market capitalization of $886.45 million, a price-to-earnings ratio of 7.82 and a beta of 0.17. The firm has a 50-day simple moving average of $16.56 and a 200-day simple moving average of $17.30. Theravance Biopharma has a 1 year low of $10.82 and a 1 year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million for the quarter. Equities analysts anticipate that Theravance Biopharma will post 1.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter worth about $101,000. Jane Street Group LLC raised its holdings in Theravance Biopharma by 169.2% in the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 88,540 shares during the last quarter. Creative Planning purchased a new position in Theravance Biopharma in the 2nd quarter worth approximately $139,000. American Century Companies Inc. lifted its position in Theravance Biopharma by 6.8% in the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after acquiring an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Theravance Biopharma by 12.4% during the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,789 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.